AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 141 min read$PBSV

Pharma-Bio Serv, Inc. (PBSV): Results of Operations and Financial Condition

Pharma-Bio Serv, Inc. (PBSV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 September 14, 2026 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026 DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology trans

Original reporting
SEC EDGAR 8-K
Published Sep 14, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PBSV
Bullish
medium confidence
Mentioned
$PBSV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PBSVBullishMed
01

Why it matters

The Q3 results show incremental revenue growth and a narrowing loss, indicating operational progress.

02

Market read

Micro‑cap earnings release with modest improvement; limited but may affect PBSV price.

03

What to watch

Potential future contracts with FDA or international regulators could amplify growth.

Relevance 7/10Novelty 6/10Timing: filed today (Sep 14, 2026)

Background

Pharma-Bio Serv provides compliance and technology transfer consulting to pharma and biotech companies across several regions.

Company-level read

Ticker impact

$PBSVBullishMedium confidence
Context

Pharma-Bio Serv reported Q3 revenue of $2.3M and a net loss of $14K, improving from prior year.

Expected impact

Potential slight upside if market rewards earnings beat.

Evidence & confidence

Micro‑cap earnings often move on any positive surprise; the improvement is modest but fresh.

Market effects

Sector

May signal modest growth for regulatory‑consulting services to pharma/biotech firms.

Regional

Limited to U.S. OTC market; no broader regional effect.

Global

Minimal; only relevant to niche compliance consulting sector.

Counterpoint

What could challenge this read

Given the tiny scale, the earnings beat may be priced in; upside limited.

Key entities

  • Executive
    Victor Sanchez

    Chief Executive Officer of Pharma-Bio Serv, quoted on earnings.

Read at source← All news

Related articles

JUN 15
$PBSVLow

Pharma-Bio Serv, Inc. (PBSV): Results of Operations and Financial Condition

Pharma-Bio Serv, Inc. (PBSV) filed an SEC Form 8-K — Results of Operations and Financial Condition. pbsv_8k.htm 0001304161 false 0001304161 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 D

SEC EDGAR 8-K2 min
SEP 14
$RLGTMed

RADIANT LOGISTICS, INC (RLGT): Results of Operations and Financial Condition

RADIANT LOGISTICS, INC (RLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RADIANT LOGISTICS ANNOUNCES RESULTS FOR THE FOURTH fiscal quarter and year ENDED June 30, 2026 Fourth-quarter growth accelerates across revenue, profitability and margin; Company positioned for future growth with extended and enhanced $200 million credit facility, an

SEC EDGAR 8-K2 min
SEP 14
$PAGPHigh

PLAINS GP HOLDINGS LP (PAGP): Results of Operations and Financial Condition

PLAINS GP HOLDINGS LP (PAGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PLAINS GP HOLDINGS, L.P. AND SUBSIDIARIES UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On November 6, 2025, Plains GP Holdings, L.P. (“PAGP”, “we”, “us”, “our”, or the “Company”) filed a Current Report on Form 8-K, as amended on a Form 8-K/A filed on

SEC EDGAR 8-K2 min
SEP 14
$HYFTMed

MindWalk Holdings Corp. (HYFT): Financial results for Q1 2027

MindWalk Holdings Corp. (HYFT) furnished an SEC Form 6-K — earnings release. 99.1 MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027 ReefIQ™ launched commercially, and a US$30 million unsecured credit facility commitment, drawn only as needed, adds balance-sheet flexibility with no dilution. AUSTIN, Texas (S

SEC EDGAR 6-K2 min
SEP 14
$PLCEHighAI 8/10

Why is Children’s Place stock down over 8% today?

Children’s Place stock fell 8.9% after reporting Q2 2026 results. Revenue dropped 18.9% to $241.8M, and net loss widened to $31.0M. Management cited operational challenges, including e-commerce transition delays. UBS lowered its price target to $3.25, maintaining a Neutral rating. The stock trades near its 52-week low of $2.04.

investing.com2 min
SEP 14
$IBPMed

Home Builders Stocks Q2 Earnings: Installed Building Products (NYSE:IBP) Best of the Bunch

Installed Building Products (NYSE:IBP) led Q2 earnings among home builders, while NVR (NYSE:NVR) reported the weakest results with revenue down 10.5% YoY. D.R. Horton (NYSE:DHI) met revenue expectations but missed full-year guidance. PulteGroup (NYSE:PHM) beat revenue and EPS estimates despite a 9.6% YoY decline. NVR, DHI, and PHM stocks are down 3%, 4.7%, and 4.8% since reporting, respectively.

yahoo.com3 min